Opus Genetics, Inc.
IRD
$2.05
$0.063.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.63M | 15.42M | 13.65M | 10.99M | 8.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.63M | 15.42M | 13.65M | 10.99M | 8.38M |
| Cost of Revenue | 28.10M | 30.67M | 30.73M | 27.59M | 24.51M |
| Gross Profit | -13.46M | -15.25M | -17.08M | -16.59M | -16.13M |
| SG&A Expenses | 24.43M | 22.34M | 19.93M | 18.20M | 14.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.81M | 52.29M | 49.95M | 45.07M | 37.86M |
| Operating Income | -37.18M | -36.87M | -36.30M | -34.07M | -29.47M |
| Income Before Tax | -68.20M | -58.28M | -58.62M | -57.53M | -27.19M |
| Income Tax Expenses | -- | -- | -- | -- | -2.00K |
| Earnings from Continuing Operations | -68.20 | -58.28 | -58.62 | -57.53 | -27.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.20M | -58.28M | -58.62M | -57.53M | -27.19M |
| EBIT | -37.18M | -36.87M | -36.30M | -34.07M | -29.47M |
| EBITDA | -37.13M | -36.84M | -36.28M | -34.07M | -29.47M |
| EPS Basic | -1.76 | -1.80 | -1.99 | -2.04 | -1.09 |
| Normalized Basic EPS | -0.53 | -0.55 | -0.67 | -0.70 | -0.68 |
| EPS Diluted | -1.76 | -1.80 | -1.99 | -2.04 | -1.09 |
| Normalized Diluted EPS | -0.53 | -0.55 | -0.67 | -0.70 | -0.68 |
| Average Basic Shares Outstanding | 198.26M | 153.77M | 116.22M | 106.85M | 99.49M |
| Average Diluted Shares Outstanding | 198.26M | 153.77M | 116.22M | 106.85M | 99.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |